Disease · MONDO_0005439
Targets17
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
1 to 17 of 17
Download this page as JSON| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| HMGCR | 3-hydroxy-3-methylglutaryl-coenzyme A reductase | 9 | HMG-CoA reductase inhibitor | Approval | https://conductscience.org/library/genes/3156 | Drugs and targets |
| PCSK9 | PCSK9 mRNA | 8 | PCSK9 mRNA RNAi inhibitor; PCSK9 mRNA rnai inhibitor; Subtilisin/kexin type 9 inhibitor | Approval | https://conductscience.org/library/genes/255738 | Drugs and targets |
| CETP | Cholesteryl ester transfer protein | 3 | Cholesteryl ester transfer protein inhibitor | Phase 3 | https://conductscience.org/library/genes/1071 | Drugs and targets |
| MTTP | Microsomal triglyceride transfer protein | 3 | Microsomal triglyceride transfer protein inhibitor | Approval | https://conductscience.org/library/genes/4547 | Drugs and targets |
| P4HB | Microsomal triglyceride transfer protein | 3 | Microsomal triglyceride transfer protein inhibitor | Approval | https://conductscience.org/library/genes/5034 | Drugs and targets |
| ANGPTL3 | Angiopoietin like 3 (ANGPTL3) mRNA | 2 | Angiopoietin like 3 (ANGPTL3) mRNA antisense inhibitor; Angiopoietin-related protein 3 inhibitor | Approval | https://conductscience.org/library/genes/27329 | Drugs and targets |
| APOB | Apo-B 100 mRNA | 2 | Apo-B 100 mRNA antisense inhibitor | Approval | https://conductscience.org/library/genes/338 | Drugs and targets |
| THRB | Thyroid hormone receptor beta | 2 | Thyroid hormone receptor beta-1 agonist | Phase 3 | https://conductscience.org/library/genes/7068 | Drugs and targets |
| ACLY | ATP-citrate synthase | 1 | ATP-citrate synthase inhibitor | Approval | https://conductscience.org/library/genes/47 | Drugs and targets |
| ASGR1 | Asialoglycoprotein receptor 1 | 1 | Asialoglycoprotein receptor 1 binding agent | Phase 2 | https://conductscience.org/library/genes/432 | Drugs and targets |
| CACNA1C | Voltage-gated L-type calcium channel | 1 | Voltage-gated L-type calcium channel blocker | Approval | https://conductscience.org/library/genes/775 | Drugs and targets |
| CACNA1D | Voltage-gated L-type calcium channel | 1 | Voltage-gated L-type calcium channel blocker | Approval | https://conductscience.org/library/genes/776 | Drugs and targets |
| CACNA1F | Voltage-gated L-type calcium channel | 1 | Voltage-gated L-type calcium channel blocker | Approval | https://conductscience.org/library/genes/778 | Drugs and targets |
| CACNA1S | Voltage-gated L-type calcium channel | 1 | Voltage-gated L-type calcium channel blocker | Approval | https://conductscience.org/library/genes/779 | Drugs and targets |
| FDFT1 | Squalene synthase | 1 | Squalene synthetase inhibitor | Phase 3 | https://conductscience.org/library/genes/2222 | Drugs and targets |
| NPC1L1 | NPC1-like intracellular cholesterol transporter 1 | 1 | Niemann-Pick C1-like protein 1 inhibitor | Approval | https://conductscience.org/library/genes/29881 | Drugs and targets |
| PTGDR | Prostaglandin D2 receptor | 1 | Prostanoid DP receptor antagonist | Phase 1 | https://conductscience.org/library/genes/5729 | Drugs and targets |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005439/targets